Controversy is swirling around the world's most expensive drug. Here's everything we just learned in a new 59-page letter from Swiss drug giant Novartis.
from Novartis's AveXis to the FDA, showing a clearer picture of how events unfolded earlier this year.
The manipulated data was used to secure approval for Zolgensma, a treatment for spinal muscular atrophy. FDA has said Zolgensma should remain on the market.'Like we were being forced to gamble with our son's life': Health insurers won't pay for a $2.1 million drug for kids, and parents say they're running out of time
The execs allegedly"altered or instructed others to alter a small amount of raw data" used in the analysis, the letter said. Novartis's AveXis But when they contacted the employee who made the allegations, the person wasn't available until about 12 days later, according to the letter. Novartis got looped in around then, in late March.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
There Doesn’t Seem to Be a Punchline Young M.A Can’t Conquer“No Mercy” is an epic, punchline filled introduction to Young M.A’s debut album, ‘Herstory.’ Hear it here
Consulte Mais informação »
Everything Jim Cramer said about the stock market on 'Mad Money,' including Trump impeachment and Bob Iger chatJim Cramer reacts to House Speaker Nancy Pelosi's move to open an impeachment inquiry into President Donald Trump, talks with Disney CEO about his new memoir and interviews GW Pharma CEO.
Consulte Mais informação »
https://people.comGet the latest news about celebrities, royals, music, TV, and real people. Find exclusive content, including photos and videos, on PEOPLE.com.
Consulte Mais informação »